CCI. CCI SHALL FULLY RELEASE, DEFEND, INDEMNIFY AND HOLD EACH MEMBER OF CONTRACTOR GROUP HARMLESS FOR, FROM AND AGAINST ALL CLAIMS ARISING OUT OF, RELATING TO, OR CONNECTED WITH THIS AGREEMENT OR THE PERFORMANCE THEREOF AND BROUGHT BY OR ON BEHALF OF ANY MEMBER OF CCI GROUP ALLEGING DAMAGE TO, LOSS OF, OR LOSS OF USE OF ANY PROPERTY OF ANY MEMBER OF CCI GROUP OR THEIR INVITEES.
CCI. CCI is an equal opportunity employer. CCI will not discriminate against any contractor, vendor or customer because of race, color, creed, religion, gender, age, veteran status, disability, citizenship, national origin or any other trait protected by federal, state or local law, regulation or ordinance. CCI is committed to taking affirmative action to ensure nondiscrimination and attainment of the goals of its Affirmative Action Plan. The cooperation and commitment of contractors, vendors and customers is necessary to achieve effective and meaningful equal employment opportunity.
CCI. On June 18, 2012, MSM India filed an application with the CCI for approval of the Transaction under the competition laws of India. On June 29, 2012, the CCI requested that MSM India supply additional information in support of its application. On July 16, 2012, MSM responded to the CCI’s request and provided the additional information requested. On July 18, 2012, the CCI requested further information from MSM India in support of its application. On July 30, 2012, MSM responded to the CCI’s request and provided the additional information requested, including a Certificate of Director of MSM India dated July 26, 2012 certifying the answer to certain information requested by the CCI. On August 9, 2012, the CCI issued a letter formally approving the Transaction. RBI/Authorized Dealer On January 25, 2013, a Form FC-TRS complete with all required supporting materials was submitted by the SPE Mauritius Companies to the Authorized Dealer for its preliminary review, which included the following documents: On May 9, 2012, the Board of Directors of Atlas adopted circular resolutions approving the Atlas SPA and certain other matters. On July 20, 2012, SPE Mauritius Investments provided a certified extract of the resolutions of its Board of Directors with respect to the Atlas SPA, the Grandway SPA, the Settlement Agreement and certain other matters. On July 20, 2012, SPE Mauritius Holdings provided a certified extract of the resolutions of its Board of Directors with respect to the Grandway SPA, the Settlement Agreement and certain other matters. On the Signing Date, Xxxxx executed a consent letter executed confirming its consent to the sale and transfer of its MSM India shares to SPE Mauritius Investments. On the Signing Date, SPE Mauritius executed a consent letter confirming its consent to its purchase the MSM India shares owned by Atlas. On the Signing Date, SPE Mauritius executed a letter of undertaking attesting to its eligibility to acquire the MSM India shares being sold by Atlas in accordance with the applicable foreign direct investment guidelines of the Government of India. On the Signing Date, MSM India executed an attestation with respect to its shareholding pattern both prior and subsequent to the sale of the MSM India shares as contemplated by the Atlas SPA and Grandway SPA. On September 25, 2012, BSR & Co. provided its valuation report on the shares of MSM India as per Reserve Bank of India guidelines. Section 281 Certificate On [_________], 2013, the De...
CCI. On June 18, 2012, MSM India filed an application with the CCI for approval of the Transaction under the competition laws of India. On June 29, 2012, the CCI requested by letter that MSM India supply additional information in support of its application. On July 16, 2012, MSM responded to the CCI’s request and provided the additional information requested. On July 18, 2012, the CCI requested further information from MSM India in support of its application. On July 30, 2012, MSM responded to the CCI’s request and provided the additional information requested, including a Certificate of Director of MSM India dated July 26, 2012 certifying the answer to certain information requested by the CCI. On August 9, 2012, the CCI issued a letter formally approving the Transaction.
CCI. RENSSELAER SHALL FULLY RELEASE, DEFEND, INDEMNIFY AND HOLD EACH MEMBER OF CONTRACTOR GROUP HARMLESS FOR, FROM AND AGAINST ALL CLAIMS ARISING OUT OF, RELATING TO, OR CONNECTED WITH THIS AGREEMENT OR THE PERFORMANCE THEREOF AND BROUGHT BY OR ON BEHALF OF ANY MEMBER OF RENSSELAER GROUP ALLEGING DAMAGE TO, LOSS OF, OR LOSS OF USE OF ANY PROPERTY OF ANY MEMBER OF RENSSELAER GROUP OR THEIR INVITEES.
CCI. The cryostorage bags containing KTE-X19 arrive frozen in a liquid nitrogen dry shipper. The bags must be stored in vapor phase of liquid nitrogen and the product remains frozen until the subject is ready for treatment to assure viable live autologous cells are administered to the subject. Several inactive ingredients are added to the product to assure viability and stability of the live cells through the freezing, thawing, and infusion process. KTE-X19 is a subject-specific product and the intended subject will be identified by a unique subject ID number. Upon receipt, verification that the product and subject-specific labels match the subject’s information (eg, initials, subject ID number) is essential. Do not infuse the product if the information on the subject-specific label does not match the intended subject. The volume of KTE-X19 infused, the thaw start/stop time, and KTE-X19 infusion start/stop time, will be noted in the subject medical record. The product must not be thawed until the subject is ready for the infusion. To date, subjects have received doses of anti-CD19 CAR T cells ranging from 0.5 - 30 x 106 anti-CD19 CAR T cells/kg. There have been no instances of accidental overdose of subjects in this program. In case of accidental overdose, treatment should be supportive. Corticosteroid therapy may be considered if any dose is associated with severe toxicity (see Section 6.8 for more information related to corticosteroid use). Investigators may additionally prescribe any other concomitant medications or treatment deemed necessary to provide adequate supportive care, including growth factor support (eg, G-CSF) and routine anti-emetic prophylaxis and treatment except those medications listed in the excluded medication Section 6.8. In subjects with Ph+ disease and who achieve CR, a TKI may be resumed 2 months after KTE-X19 infusion at the investigator discretion and in accordance with institutional guidelines. See Section 3, Table 2 for use of TKI’s during bridging chemotherapy. The investigator is responsible for reporting all concomitant medications as follows in Table 3: Table 3. Reporting Requirements for Concomitant Medications Subjects who are pre- screen or screen-fails Subjects who are enrolled, but do not receive KTE-X19 infusion Subjects who are enrolled and receive KTE-X19 infusion Concomitant therapies related to serious adverse event(s) will be recorded from the date of the pre- screening informed consent or screening informed consen...
CCI. SIGNAL HILL SHALL FULLY RELEASE, DEFEND, INDEMNIFY AND HOLD EACH MEMBER OF CONTRACTOR GROUP HARMLESS FOR, FROM AND AGAINST ALL CLAIMS ARISING OUT OF, RELATING TO, OR CONNECTED WITH THIS AGREEMENT OR THE PERFORMANCE THEREOF AND BROUGHT BY OR ON BEHALF OF ANY MEMBER OF SIGNAL HILL GROUP ALLEGING DAMAGE TO, LOSS OF, OR LOSS OF USE OF ANY PROPERTY OF ANY MEMBER OF SIGNAL HILL GROUP OR THEIR INVITEES.
CCI. The authorized capital stock of CCI is as set forth on Schedule 5.6. All of the outstanding shares of capital stock of CCI are duly authorized, validly issued, fully paid and nonassessable. As of the close of business on March 31, 1998, the number of shares of capital stock of CCI issued and outstanding and the number of shares held in the treasury of CCI are as set forth on Schedule 5.6. Except as disclosed in the CCI SEC Reports, all outstanding shares of capital stock of the Significant Subsidiaries (as defined for purposes of Regulations S-X under the Exchange Act) of CCI are owned by CCI or a direct or indirect wholly-owned Subsidiary of CCI, free and clear of all liens, charges, encumbrances, claims and options of any nature. As of the close of business on March 31, 1998, there were outstanding options to acquire no more than the number of shares of CCI capital stock set forth on Schedule 5.6.
CCI. The CIC regimen should be maintained throughout the study;
CCI. 9. Must not require antiarrhythmic and/or antidiuretic therapy for heart failure. Patients are allowed to take other medication including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs), β blockers or potassium, provided they have been on a stable dose for 24 weeks prior to study drug administration and the dose is expected to remain constant throughout the study.
